New Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib’s Potential to Change the Treatment Paradigm for IDH-Mutant Diffuse Glioma
Improving the lives of our patients
We work tirelessly to deliver meaningful therapeutic progress to the patients we serve.